Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis of patients with ST-elevation myocardial infarction presenting to the emergency department without chest pain: a retrospective nationwide cohort study.

Heart (British Cardiac Society)·2026
Same author

Epicardial adipose tissue signatures in Asian coronary artery disease: Insights from cardiac CT.

American journal of preventive cardiology·2026
Same author

Cardiac-targeted delivery of advanced medical therapies for heart disease.

European heart journal·2026
Same author

Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study.

Infectious diseases and therapy·2026
Same author

Proteins targeting ischaemic-reperfusion injury and repair after myocardial infarction: a systematic literature review.

Cardiovascular research·2026
Same author

Mitochondrial Dynamic Proteins MiD49 and MiD51 as Novel Targets of Cardioprotection.

Cells·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
Same journal

Pharmacological Insights into Medicinal Plants and Phytomolecules for the Management of Alopecia with Mechanistic Perspectives and Therapeutic Potential.

Current pharmaceutical design·2026
Same journal

Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical Formulations.

Current pharmaceutical design·2026
Same journal

The Mechanism of Huaiqihuang in the Treatment of Nephrotic Syndrome: An Integrated Study Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.

Current pharmaceutical design·2026
Same journal

Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.

Current pharmaceutical design·2026
Same journal

The Use of Hemostatic Agents in Traumatic Bleeding: One Size Does Not Fit All.

Current pharmaceutical design·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
07:52

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science).

Derek J Hausenloy1

  • 1The Hatter Cardiovascular Institute, University College London Hospital & Medical School, 67 Chenies Mews, London, WC1E 6HX, UK. d.hausenloy@ucl.ac.uk

Current Pharmaceutical Design
|December 29, 2012
PubMed
Summary
This summary is machine-generated.

Ischemic heart disease (IHD) poses a global health challenge. This review explores endogenous cardioprotective strategies like ischemic preconditioning (IPC) and remote ischemic conditioning (RIC) to mitigate myocardial ischemia-reperfusion injury (IRI) and preserve heart function.

More Related Videos

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
10:13

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Experiment Videos

Last Updated: May 15, 2026

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
07:52

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
10:13

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Area of Science:

  • Cardiovascular Medicine
  • Physiology
  • Pathology

Background:

  • Ischemic heart disease (IHD) is a primary cause of global mortality and morbidity.
  • Acute ischemia-reperfusion injury (IRI) significantly contributes to IHD's pathological consequences.
  • Effective cardioprotection strategies are crucial for improving clinical outcomes in IHD patients.

Purpose of the Study:

  • To review endogenous cardioprotective strategies for myocardial protection against IRI.
  • To explore the characteristics and signaling mechanisms of ischemic preconditioning (IPC), ischemic postconditioning (IPost), and remote ischemic conditioning (RIC).
  • To provide an overview based on pre-clinical experimental literature.

Main Methods:

  • Literature review of pre-clinical experimental studies on endogenous cardioprotective strategies.
  • Analysis of major characteristics and underlying signaling pathways.
  • Focus on strategies relevant to acute myocardial IRI.

Main Results:

  • Identified IPC, IPost, and RIC as promising endogenous cardioprotective approaches.
  • Detailed the signaling mechanisms involved in these conditioning strategies.
  • Highlighted their potential for protecting the myocardium during IRI.

Conclusions:

  • Endogenous cardioprotective strategies offer novel therapeutic avenues for IHD.
  • Understanding their mechanisms is key to clinical application.
  • These strategies show potential for preserving cardiac function in acute IRI settings.